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Background: This very large population-based study investigated outcomes after a diagnosis of prostate cancer
(PCa) in terms of mortality rates, treatments and adverse effects.
Methods: Among the 11 million men aged 40 years and over covered by the general national health insurance
scheme, those with newly managed PCa in 2009 were followed for two years based on data from the national
health insurance information system (SNIIRAM). Patients were identified using hospitalisation diagnoses and specific
refunds related to PCa and PCa treatments. Adverse effects of PCa treatments were identified by using hospital
diagnoses, specific procedures and drug refunds.
Results: The age-standardised two-year all-cause mortality rate among the 43,460 men included in the study was
8.4%, twice that of all men aged 40 years and over. Among the 36,734 two-year survivors, 38% had undergone
prostatectomy, 36% had been treated by hormone therapy, 29% by radiotherapy, 3% by brachytherapy and 20%
were not treated. The frequency of treatment-related adverse effects varied according to age and type of treatment.
Among men between 50 and 69 years of age treated by prostatectomy alone, 61% were treated for erectile
dysfunction and 24% were treated for urinary disorders. The frequency of treatment for these disorders decreased
during the second year compared to the first year (erectile dysfunction: 41% vs 53%, urinary disorders: 9% vs 20%).
The frequencies of these treatments among men treated by external beam radiotherapy alone were 7% and 14%,
respectively. Among men between 50 and 69 years with treated PCa, 46% received treatments for erectile dysfunction
and 22% for urinary disorders. For controls without PCa but treated surgically for benign prostatic hyperplasia, these
frequencies were 1.5% and 6.0%, respectively.
Conclusions: We report high survival rates two years after a diagnosis of PCa, but a high frequency of PCa
treatment-related adverse effects. These frequencies remain underestimated, as they are based on treatments for
erectile dysfunction and urinary disorders and do not reflect all functional outcomes. These results should help
urologists and general practitioners to inform their patients about outcomes at the time of screening and diagnosis,
and especially about potential treatment-related adverse effects.
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Population-based studyBackground
The availability of serum prostate-specific antigen (PSA)
testing has led to a dramatic increase in the incidence of
localised prostate cancer (PCa), corresponding to well or
moderately differentiated tumours with a low risk of
progression [1-4]. The discordant results of randomised* Correspondence: philippe.tuppin@cnamts.fr
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unless otherwise stated.studies concerning the impact of PSA testing on mortality
and the adverse effects of treatments contribute to the de-
bate on overdiagnosis and overtreatment of PCa [4-13].
Adverse effects on sexual and urinary functions are
due to specific pathophysiological mechanisms related to
each of the main treatment modalities, e.g., radical prosta-
tectomy, brachytherapy, external beam radiotherapy and
hormone therapy. Patient quality of life is usually estimated
by assessment tools filled in by the patient or completedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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2000 individuals [7-13]. The frequency of symptoms
is generally high, but depends on the definition used
for urinary and erectile problems, as well as on practices,
measurement tools and monitoring periods. Quality of life
assessment rarely includes comparisons with a control
group without PCa.
The purpose of this observational study based on a
large population of French men aged 40 and over with
newly managed PCa in 2009 was to estimate the two-year
all-cause mortality according to the various treatments for
PCa, and the frequency of PCa treatments and their
adverse effects, when they required health care resources,
for survivors compared to two control groups.
Methods
Population and data source
All data were obtained from the French National Health
Insurance Information System (SNIIRAM) [14]. Access to
data and data analysis are granted by decree only for a
period of three years plus the current year and authorisa-
tion from the French Data protection Authority (Commis-
sion nationale de l'informatique et des libertés, CNIL) must
also be obtained. This database comprehensively records
all hospitalisations, prescriptions, health care services and
procedures reimbursed together with their dates. Drugs are
identified using their ATC (Anatomical Therapeutic Classi-
fication) code, while medical and surgical procedures are
identified by a specific classification. The SNIIRAM does
not contain any medical information concerning results
related to prescriptions or examinations. It nevertheless
includes information on the presence of long-term chronic
diseases (LTCD), such as PCa, eligible for 100% reimburse-
ment of health care expenditure, after approval by a na-
tional health insurance consultant physician. LTCD status
is granted at the time of diagnosis of the disease and is
renewable for five years. These chronic diseases and hos-
pital diagnoses are coded according to the International
Classification of Diseases (ICD 10). The SNIIRAM also in-
cludes a permanent sample (EGB: échantillon généraliste
des bénéficiares) of individuals selected at random from
1/97th of all beneficiaries of the French general health
insurance schemes, i.e. approximately 600,000 individuals.
The study population was composed of men aged
40 years and over, covered by the general health insurance
scheme, with newly managed PCa in 2009. In 2009, 73%
of French men aged 40 and over (11 million people) were
covered by the general health insurance scheme. The rest
of the French population was covered by other specific
health insurance schemes. One of the reasons for limiting
the study to individuals covered by the general scheme
was the availability of survival status and date of death
from the National Institute for Statistics and Economic
Studies for the study period.Definitions and data analysis
Men with PCa were identified by the presence of at least
one of the following criteria in 2009: a hospital stay with
a PCa code as primary diagnosis, PCa in situ or prostate
tumour with an unpredictable course; LTCD for PCa;
hospitalisation for radical prostatectomy, subcapsular or-
chidectomy or specific brachytherapy; hospitalisation for
chemotherapy or radiotherapy with a PCa-related diag-
nosis; at least one reimbursement for GnRH analogues,
antiandrogens or oestrogens and estramustine. To select
only newly diagnosed cases in 2009, men with any of the
above criteria in 2008 were excluded.
PCa treatments and their combinations were identified
during the two-year follow-up after the first treatment
criterion identified in 2009. Two groups of patients with-
out treatment over the next two years were formed: one
group with a hospitalisation corresponding to a primary
diagnosis of PCa (with or without LTCD for PCa in 2009)
and the other group with only LTCD status for PCa granted
in 2009. These patients were considered to be on watchful
waiting for PCa. For the study of treatment combinations,
subcapsular orchidectomy, which is rarely performed, was
grouped together with hormone therapy.
Complications were defined on the basis of at least
one hospitalisation with a main diagnosis corresponding
to the specific codes of complications or the presence of
a surgical procedure to treat these complications. Urinary
disorders were identified by reimbursements of external
devices to treat incontinence (urine collectors and penile
sheaths). Reimbursements of specific drugs were also
considered (ATC G04BD: oxybutynin, flavoxate, trospium
and solifenacin). Erectile dysfunction was identified by
reimbursements for penile prostheses or intracavernous
injections of vasoactive agents (sildenafil was not reim-
bursed). Drug treatments were defined on the basis of at
least one reimbursement for specific drugs for patients
still alive at one year and at two years.
The two-year mortality rate for patients with treated
PCa was compared to that of all male health insurance
beneficiaries aged 40 years and over. A standardised
mortality ratio (SMR) was calculated for each age group
and the overall SMR was age-standardised using data for
men aged 40 years and over in the general scheme. Fre-
quencies of treatments and complications were studied
among men of the general scheme who were still alive
with a follow-up of two years. Among men between the
ages of 50 and 69, complication rates according to the
type of medical treatment were compared to those of
two control groups without PCa, selected from the EGB
according to the presence of a surgical or endoscopic
procedure performed for BPH between 2008 and 2011.
The 50–69 years age-group was selected because radical
prostatectomy, associated with a higher complication
rate than other treatments, is more frequent at these
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tion and quality of life and is therefore more frequently
treated. The frequencies for each of these groups were
age-standardised for all males aged 50–69. Chi-square
tests were used to compare frequencies between groups.
Statistical analyses were performed using SAS Enterprise
Guide 4.3 software (SAS Institute Inc., Cary, NC, USA).
Results
Survival
Newly diagnosed PCa in 2009 was found in 43,460 men
with a mean age of 70.2 years. The crude one-year and
two-year all-cause mortality rates were 7% and 13%, re-
spectively, and the age-standardised rates were 4.6% and
8.4%, respectively (Table 1). The age-standardised mor-
tality rate was slightly higher before the age of 50 (7%)
and was 47% for men aged 85 years and over. The patients
of this population had a significant excess two-year all-
cause mortality rate compared to all men aged 40 and
over (SMR= 2). The SMR was higher for the youngest age
groups. In this group of 43,460 patients, 1,169 subjects
still alive at two years were excluded because they were no
longer covered by the general health insurance scheme or
had been admitted to an institution that managed medi-
cinal products directly with no reimbursements reported
in the SNIIRAM database.
Age-standardised two-year mortality rates varied accor-
ding to age and type of PCa treatment (Table 2). Lowest
two-year mortality rates were observed for patients treated
by radical prostatectomy (4%) and hormone therapy (9%)Table 1 One-year and two-year mortality rates among men w
comparison with all male general scheme beneficiaries aged
40-49 50-54 55-59 60-64 6
Patients with cancer
N 478 1,567 4,079 7,371 7
% 1.1 3.6 9.4 17.0 1
One-year follow-up
Patients still alive* 443 1,481 3,857 7,026 7
Deceased
N 15 40 101 186
% 3.3 2.6 2.6 2.6
Two-year follow-up
Patients still alive* 414 1,433 3,727 6,782 6
Deceased
N 31 71 192 369
% 7.0 4.7 4.9 5.2
SMR§ 11.4 3.7 2.6 2.1
*Excluding deaths, regime changes and patients lost to follow-up.
**Age-standardised.
§p < 0.001 for all SMR.and highest two-year mortality rates were observed for pa-
tients treated by external beam radiotherapy (14%
overall, and 30% for those treated by external beam
radiotherapy alone) and chemotherapy (38%). The two-
year mortality rate for men not treated for PCa was 15%
for men hospitalised for PCa and 8% for men with only
LTCD status.
Prostate cancer treatment
In the population of 36,734 men with PCa still alive after
two years, 38% had been treated by radical prostatec-
tomy, 35% by hormone therapy, 29% by external beam
radiotherapy, 2.5% by brachytherapy, 0.3% by subcapsular
orchidectomy and 1.6% by chemotherapy (2). Twenty per
cent of patients had not received any active treatment, but
had been hospitalised with a specific code for PCa (15%)
or had been granted LTCD status (5%).
The frequency of prostatectomy decreased from 67%
in men between the ages of 50 and 54 to 6% among men
between the ages of 75 and 79. The frequency of hormone
therapy, stable at around 20% between the ages of 50 and
64, increased to 65% for men aged 80 and over. The
frequency of external beam radiotherapy reached a peak
of 41% in men between the ages of 75 and 79. The most
common treatment combination was hormone therapy
and external beam radiotherapy (13%). Prostatectomy was
often performed alone (31%), especially among the youn-
gest patients (more than half), and was combined with
radiotherapy and hormone therapy in only 2% of men
treated for PCa.ith newly managed prostate cancer in 2009 by age and
40 and over, according to age after two years
5-69 70-74 75-79 80-84 85 and over All ages
,435 7,876 6,663 4,351 3,640 43,460
7.1 18.1 15.3 10.0 8.4 100.0
,070 7,368 6,022 3,568 2,526 39,361
242 392 532 727 1,047 3,282
3.3 5.1 8.1 16.9 29.3 4.6**
,792 7,033 5,554 3,106 1,893 36,734
456 665 948 1,159 1,656 5,547
6.3 8.6 14.6 27.2 46.7 8.4**
1.9 1.8 1.9 2.1 1.9 2.0**
Table 2 Age-standardised two-year mortality rates among men with newly managed prostate cancer (PCa) in 2009
according to treatment, and frequency of treatments and their combinations among men still alive at two-years
according to age
Death rate Frequency of treatment
Age-standardised 40-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 ≥85 Total
N 43,460 414 1,433 3,727 6,782 6,792 7,033 5,554 3,106 1,893 36,734
Treatments (at least one) % % % % % % % % % % %
Total prostatectomy 4.3 46.9 66.9 65.8 60.6 54.2 32.4 6.0 0.2 0.3 38.1
- laparoscopy 3.5 20.3 37.7 36.6 33.2 30.9 19.7 3.8 0.1 0.2 21.6
- laparotomy 5.1 26.6 29.2 29.2 27.4 23.3 12.7 2.1 0.1 0.1 16.5
Hormone therapy 9.4 40.3 21.4 20.3 20.5 25.4 34.9 53.3 65.4 66.8 35.5
Subcapsular orchidectomy 12.7 1.2 0.3 0.2 0.1 0.1 0.2 0.4 1.2 1.3 0.3
Chemotherapy 38.5 4.3 2.5 1.6 1.6 1.4 1.5 1.7 1.8 1.1 1.6
Brachytherapy 0.8 2.4 3.0 4.2 4.0 2.8 2.7 1.2 0.1 0.0 2.5
External beam radiotherapy 14.0 18.4 21.1 24.8 26.0 28.8 39.7 40.6 12.2 3.5 28.6
No treatment*: 13.6 12.1 13.9 14.7 16.9 17.8 20.7 24.6 30.2 31.2 20.4
- Hospitalisation with PCa diagnosis 15.0 10.4 11.0 11.5 12.8 13.6 15.3 17.9 22.9 25.5 15.5
- Isolated LTCD for PCa 8.1 1.7 2.9 3.2 4.2 4.2 5.3 6.7 7.2 5.7 4.9
Treatment combinations % % % % % % % % % % %
Prostatectomy, all types
Alone 4.4 37.4 53.5 52.3 49.4 43.7 25.4 4.8 0.2 0.1 30.6
Combined with:
- Hormone therapy 1.2 1.9 3.6 3.4 2.8 3.0 2.1 0.6 0.0 0.1 2.1
- External beam radiotherapy 4.2 4.1 5.7 5.6 5.0 4.1 2.8 0.4 0.0 0.0 3.1
- External beam radiotherapy 0.4 2.9 4.0 4.1 3.2 3.2 1.9 0.3 0.0 0.0 2.2
+ Hormone therapy
Hormone therapy
Alone 9.5 28.3 6.8 4.0 3.8 5.6 9.8 26.4 55.9 64.0 16.6
Combined with:
- External beam radiotherapy 8.9 4.3 4.9 6.7 8.7 11.6 19.1 23.9 8.5 2.5 12.8
External beam radiotherapy alone 30.0 2.2 2.5 3.4 4.7 6.7 12.9 14.3 3.0 0.7 7.5
LTCD: long term chronic disease status.
*Absence of the above treatments during the two-year follow-up.
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In the population of 36,734 men with PCa still alive after
two years, regardless of the PCa treatment, 54% presen-
ted no health care consumption corresponding to adverse
effects of PCa treatments (Table 3).
The frequency of reimbursement for at least one intra-
cavernous injection for erectile dysfunction was 21% for
all ages and ranged between 33% and 47% for men
under the age of 65. A penile prosthesis was used by
0.2% of men under 55 years of age. The frequency of
reimbursement for drugs used to treat urinary disorders
was 15% for all ages, and varied slightly according to age
(from 9% to 17%), while external devices were reimbursed
in 4.8% of cases and 1% of cases were treated by surgery.
The frequency of surgical procedures for acute urinary
retention was 11% for all ages, but was higher amongolder men. Surgical treatment of complications was more
common during the first year of follow-up.
The frequency of treatment for adverse effects varied
according to the type of PCa treatment (Table 4). Among
patients between the ages of 50 and 69, intracavernous
injection for erectile dysfunction was more common for
patients treated by prostatectomy alone (61%) compared
to patients treated by radiotherapy alone (7%). Similar
results were observed for urinary disorders, with reim-
bursement of drugs in 18% versus 12% of patients and
reimbursement of external devices in 8% and 2% of pa-
tients, respectively. Patients treated by prostatectomy
alone more frequently received reimbursements for drugs
used to treat erectile dysfunction than those treated by
prostatectomy combined with external beam radiotherapy
or hormone therapy.
Table 3 Frequency of treatments* for various complications, according to age, among men with newly managed
prostate cancer in 2009, still alive after two years
40-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 ≥85 All ages
Complications 414 1,433 3,727 6,782 6,792 7,033 5,554 3,106 1,893 36,734
% % % % % % % % % %
Erectile dysfunction 34.1 46.9 43.9 37.1 27.6 11.8 2.1 0.5 0.1 21.2
Intracavernous injection 33.8 46.7 43.8 37.0 27.5 11.7 2.0 0.4 0.1 21.1
Penile prosthesis 0.2 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.1
Urinary disorders 14.0 20.4 20.5 19.4 21.8 19.5 17.1 14.6 14.4 18.9
Drug treatment 10.6 15.6 16.4 14.7 17.1 15.9 14.5 11.6 9.3 15.0
External devices 3.9 6.1 5.6 5.8 6.2 4.8 2.6 2.8 4.2 4.8
Surgical procedure 1.0 1.0 1.3 1.4 1.6 1.2 0.4 0.1 0.0 1.0
Clot removal
Surgical procedure 1.2 1.4 1.0 1.3 1.0 1.3 1.4 1.9 2.3 1.4
Urethral stricture
Surgical procedure 1.4 1.5 1.4 1.5 2.0 2.4 2.0 2.0 2.6 1.9
Bladder neck stenosis
Surgical procedure 1.4 2.2 1.7 1.8 1.9 2.0 1.8 1.3 1.2 1.8
Radiation-induced inflammation
Hospitalisation 0.0 0.6 0.5 0.6 0.9 1.4 2.0 0.5 0.1 1.0
Acute urinary retention
Surgical procedure 5.1 3.8 5.4 7.5 8.6 12.6 17.2 20.6 19.4 11.5
Urethral or rectal fistula
Hospitalisation 0.7 0.4 0.2 0.2 0.3 0.1 0.1 0.0 0.0 0.2
None 55.1 40.5 40.5 45.2 49.4 60.0 65.4 66.4 64.3 54.1
Drug treatment
Antidepressants 14.5 15.6 12.4 9.2 9.4 9.3 11.6 15.9 18.8 11.3
Anxiolytics 19.3 19.0 17.2 15.0 15.4 17.0 18.2 21.7 23.9 17.4
*Hospitalisation: primary diagnosis, surgical treatment: presence of a specific surgical procedure code, external devices and medication: reimbursement codes.
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medication for erectile dysfunction, 12% had received
medication for urinary disorders, and 19% had received
medication for acute urinary retention. For the subgroup
of patients not hospitalised for PCa, these frequencies
were 20%, 12% and 5%, respectively. In contrast, the fre-
quencies of the various treatments for erectile dysfunc-
tion and urinary disorders in the two control groups
without PCa were very low, even in men who had
undergone BPH surgery. The highest treatment frequen-
cies observed in these men concerned medication for
urinary disorders (4.8%), acute urinary retention (3.6%)
and, to a lesser degree, erectile dysfunction (1.5%).
The frequency of treatment for erectile dysfunction
decreased during the second year compared to the
first year among patients treated by radical prostatec-
tomy and patients with untreated PCa, while the fre-
quency of treatment for erectile dysfunction increased
between the first and second year among men treated
by external beam radiotherapy alone. The frequencyof drug treatment for urinary disorders decreased during
the second year for men treated by prostatectomy and
men with untreated PCa. However, men with untreated
PCa had a high frequency of treatment for acute urinary
retention.
Discussion
This study reports outcomes for men diagnosed with
PCa based on health care consumption data concerning
a very large population followed for two years. We re-
port a low 8% mortality rate which is nevertheless two-
fold higher than that of the general male population and
a higher frequency of radical treatments in men under
the age of 70. Very high frequencies of erectile dysfunc-
tion and urinary disorders requiring treatment were ob-
served among men between the ages of 50 and 69
treated by radical prostatectomy, compared to controls
and men with untreated PCa.
This study demonstrated a crude one-year survival
rate of 95% with variations related to age, which is
Table 4 Frequencies of the various complications according to type of treatment* among men aged between 50 and
69 with newly managed prostate cancer (PCa) in 2009 and still alive after two years, and comparison with two control













N 9,035 2,159 941 882 15,623 3,107 43,099 1,026
Mean age (years) 61.8 61.8 63.6 62.4 62.1 62.5 57.8 60.5
Complications % % % % % % %
Erectile dysfunction
Two years 61.4 47.9° 7.2° 6.8° 45.8 9.6° 0.3° 1.5°
Drug treatment 61.3 47.9 7.2 6.8 45.7 9.5 0.3 1.5
Penile prosthesis 0.2 0.2 0.04 0.0 0.2 0.1 0.00 0.00
First year 53.2 38.1° 2.6° 4.7° 38.7 8.1° 0.2° 1.0°
Drug treatment 53.1 38.1 2.6 4.7 38.6 8.0 0.2 1.0
Penile prosthesis 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Second year 41.5 31.8° 6.3° 4.4° 30.8 6.4° 0.2° 1.1°
Drug treatment 41.3 31.8 6.3 4.4 30.7 6.3 0.2 1.1
Penile prosthesis 0.2 0.2 0.0 0.0 0.1 0.0 0.0 0.0
Urinary disorders
Two years 23.7 27.9° 14.4° 8.7° 21.6 12.3° 0.4° 5.6°
Drug treatment 18.0 21.6 12.3 7.4 17.0 9.4 0.3 4.8
External devices 7.7 9.3 2.4 1.8 6.3 3.8 0.1 0.8
Surgical procedure 2.1 1.2 0.00 0.1 1.4 0.6 0.00 0.00
First year 20.1 22.8 10.9° 4.7° 17.5 10.4° 0.2° 3.7°
Drug treatment 14.7 16.0 8.9 4.0 13.1 7.5 0.2 3.2
External devices 7.2 8.9 2.2 1.1 5.8 3.3 0.1 0.5
Surgical procedure 0.5 0.2 0.0 0.1 0.3 0.5 0.0 0.0
Second year 9.0 11.5° 7.6 6.0° 9.0 5.5° 0.2° 3.5°
Drug treatment 7.2 10.3 5.7 4.8 7.6 4.2 0.2 3.0
External devices 1.4 1.5 1.9 1.2 1.3 1.6 0.1 0.4
Surgical procedure 1.7 1.0 0.0 0.1 1.1 0.2 0.0 0.0
Clot removal
Surgical procedure 1.2 1.2 1.0 1.3 1.2 1.2 0.00° 0.3°
Urethral stricture
Surgical procedure 1.6 1.9 1.5 1.1 1.4 2.2 0.0° 1.3
Bladder neck stenosis
Surgical procedure 2.0 2.2 0.3° 1.0° 1.9 1.7 0.00° 0.9°
Radiation-induced
inflammation
Hospitalisation 0.0 1.1° 3.2° 0.1 0.7 0.3° 0.00° 0.00°
Acute urinary retention
Surgical procedure 1.4 1.3 12.2 9.9° 3.5 19.3° 0.00° 3.6
Urethral-rectal fistula
Hospitalisation 0.5 0.4 0.00 0.1° 0.3 0.0° 0.00° 0.00°
None 28.1 35.8° 69.3° 76.9° 40.1 63.5° 99.3° 89.0°
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Table 4 Frequencies of the various complications according to type of treatment* among men aged between 50 and
69 with newly managed prostate cancer (PCa) in 2009 and still alive after two years, and comparison with two control
groups without PCa, with or without surgical treatment for benign prostatic hyperplasia (BPH) (Continued)
Drug treatment
Antidepressants 11.3 11.4 12.2 15.9 12.0 12.2 7.1° 11.7
Anxiolytics 15.3 18.1 21.1° 19.8 17.1 15.0° 10.4° 16.5
*Hospitalisation: primary diagnosis, surgical treatment: presence of a specific surgical procedure code, external devices and medication: reimbursement codes.
**Patients without treatment during the two years but with a primary diagnosis of PCa during hospitalisation or long-term chronic disease status for PCa.
***External beam radiotherapy and/or hormone therapy.
Frequencies are age-standardised for men aged between 50 and 69 covered by the general scheme.
°p < 0.05 for comparisons of frequencies between prostatectomy alone and prostatectomy combined with another treatment, external beam radiotherapy, for
comparisons between untreated PCa and treated PCa, for comparisons between treated PCa and each control group.
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one-year overall survival, and a specific survival rate of
96%) [15]. Causes of death other than PCa were reported
for 80% of deceased patients in the United States and
65% of deceased patients in Sweden [16]. Patients with
PCa, especially with metastatic disease, presented a
higher risk of death by suicide or cardiovascular disease
than the general population [17]. These data highlight
the high survival rate and the fact that mortality is due
to causes other than PCa. Although no information was
available concerning specific mortality rates, the two-
year mortality rate in this population was twofold higher
than that of men covered by the general health insur-
ance scheme. More specifically, the highest SMR was
observed for the 40–49 year age-group, which was less
frequently treated by prostatectomy and more frequently
treated by chemotherapy and hormone therapy, which
could suggest more advanced disease, although no infor-
mation on disease stage was available in our database.
In this study, the estimated frequencies of the various
treatments for PCa were 38% for prostatectomy, 35% for
hormone therapy, 29% for external beam radiotherapy
and 20% of patients did not receive any treatment during
the two-year follow-up. This group can be considered to
correspond to watchful waiting, but some of these patients
may have received treatment for PCa before 2008 and
were wrongly considered to have newly diagnosed PCa.
However, it is much more likely that the watchful waiting
group was underestimated, as newly diagnosed patients
who were not hospitalised and who did not require treat-
ment or LTCD status were not included in this database.
A French registry study conducted in 2001 on 1,840 men
of all ages with stage T1 or T2 PCa reported slightly lower
frequencies for prostatectomy (31%) and hormone therapy
(22%) and nearly the same rate for radiotherapy (26%) and
watchful waiting (19%) [18]. The proportion of patients
managed by watchful waiting has most likely increased
since 2001. The more recent Swedish registry provides dif-
ferent figures. Among the 31,903 patients of all ages with
localised PCa between 1996 and 2006, 41% had undergone
prostatectomy (66% between 55 and 59 years of age, as for
all stages in this study), 20% had received external beamradiotherapy (24% for those between 65 and 69) and 30%,
a very high proportion, were on watchful waiting [19].
The Australian state of New South Wales registry showed
that, in a group of 1,636 patients under the age of 70 with
localised PCa between 2000 and 2002, 60% had been
treated by prostatectomy, 28% by external beam radiother-
apy, 14% by hormone therapy and 12% by watchful wait-
ing [8]. For the same age-group, at all stages, our study
found similar frequencies for prostatectomy (60%) and
external beam radiotherapy (26%) but higher frequencies
for hormone therapy (23%) and watchful waiting (16%).
The choice of treatment probably varies from one series
to another depending on the tumour grades included, the
study period, patient characteristics and comorbidity.
However, it is very likely that the choice of treatment also
depends on PCa screening frequency and medical prac-
tices. For example, brachytherapy is less commonly used
in France [20].
This study demonstrated a very high rate of PCa
treatment-related adverse effects. Over a 2-year period,
treatments for urinary and erectile disorders were repor-
ted in 19% and 21% of all men with newly diagnosed
Pca, respectively. These rates were even higher among
men aged 50–54 years (20% and 47%) and men of all
ages who had undergone prostatectomy (24% and 61%).
In contrast with studies on urinary disorders and erectile
dysfunction based on the presence of symptoms or quality
of life assessment, using various definitions and instru-
ments, in the present study, these disorders were estimated
on the basis of health care consumption. These estimates
depend on the patient’s perception of the disorder,
the efficacy of treatment of the disorder and the physician’s
or surgeon’s impression.
These adverse effect rates, although underestimated,
can nevertheless be considered to accurately reflect the
impact of PCa treatments on quality of life. Specific
health care consumption was very rare in the control
group without PCa and who had not undergone BPH
surgery. As expected, treatment rates for acute urinary
retention and urinary disorders were higher among con-
trols that had undergone BPH surgery. Higher rates of
treatment for acute urinary retention were observed for
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PCa, which may be linked to tumour progression [13].
As also reported in quality of life studies, lower rates of
adverse effects were observed after external beam radio-
therapy than after prostatectomy [7–13]. In our study,
surgery for incontinence during the two years following
prostatectomy was performed in 2.1% of patients versus
2.6% in a Canadian study based on 25,436 patients of all
ages with a five-year follow-up [21,22]. Patients treated
by prostatectomy in combination with another treatment
such as hormone therapy also had a lower rate of treat-
ment for erectile disorders, which could be explained by
the lack of available treatment for sexual dysfunction
induced by hormone therapy.
Urinary disorders and erectile dysfunction are much
less common after external beam radiotherapy: 7% of
patients experienced erectile dysfunction and 15% experi-
enced urinary disorders. A recent American study based
on 1,201 patients of all ages with stage T1 or T2 PCa
between 2003 and 2006, analysing first-line treatments,
reported urinary disorders in 30% of patients after two
months and 7% of patients after two years [10]. The
present study showed lower rates of adverse effects of
treatment after the first year following PCa treatment, in
line with the results of quality of life studies that reported
improvement of symptoms after the first year of treat-
ment, with an impact on quality of life, but without return
to baseline conditions [7,8,10,11].
This study presents a number of limitations. Certain
groups of the French population (25%) were not included
due to their occupation, such as civil servants, liberal pro-
fessions and farmers, which may influence epidemiological
characteristics (exposure) or health care consumption, and
who are covered by other health insurance schemes. The
data of this study were derived from administrative data-
bases comprising the classical limitations concerning the
modalities of data collection and coding. However, these
databases are useful for economic purposes for hospitals
and ambulatory services, which could be an argument in
favour of the quality and exhaustiveness of data on the
medicinal products and health care provided. The avail-
ability of data for a period of three years plus the current
year constitutes a limit to the duration of follow-up of
prospective studies, especially concerning medium-term
or long-term adverse effects, such as those of hormone
therapy. Some products, such as sildenafil or vacuum
pumps, are not reimbursed. The database does not include
any information on PCa stage, type of tumour or the se-
verity of the disorders, in contrast with qualitative studies,
and only allows analysis of treatments prescribed and
reimbursed. PCa considered to be newly managed could
also correspond to recurrences requiring further treat-
ment, but a one- to two-year treatment-free period
prior to inclusion was required. These patients werealso required to have LTCD status for PCa granted before
2009. As already emphasized, outcomes based on health
care consumption data may not reflect all complications
experienced nor their severity, but this aspect must be
considered case by case for each database [23,24]. The
strengths of our observational study are that it was based
on a very large, comprehensive population of men covered
by the French national health insurance scheme and com-
prised comparisons with control groups. Given the differ-
ences in health care systems between Western countries,
the results of this study cannot be directly extrapolated in
other settings. In France, PCa incidence was estimated to
be 71,000 cases for 2011 using data from regional cancer
registries. Recently, a new estimation provided a lower in-
cidence of 53,465 cases for 2009. National extrapolation of
the 43,460 cases of PCa in 2009 identified by this study
would give an incidence of 59,500 cases, close to the 2009
estimation.
Conclusions
In this population of men with treated or diagnosed
PCa, we report, as expected, a high two-year survival
rate and describe the frequencies of various PCa treat-
ments. More importantly, we report a high frequency of
men treated for adverse effects induced by PCa treat-
ments, especially prostatectomy. These results can be
used as a basis to provide patients with information
about outcomes at the time of screening and diagnosis,
and to choose treatments according to national guide-
lines and PCa clinical characteristics.
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